Sign in Subscribe
Cancer research

Genetic Immunotherapy Shows Promise in Lung Cancer Treatment

Strategic Insights

— 1 min read

Researchers in Korea have made a significant breakthrough in the fight against lung cancer with the development of a novel genetic immunotherapy approach. The study, published in Cancer Gene Therapy, demonstrates the efficacy of combining conditionally replicating adenovirus (CRAd) and replication-defective adenovirus expressing interferon-beta (ad-IFN-beta) in treating lung cancer. This innovative approach has shown promising results in reducing tumorigenicity and enhancing cytotoxic T-lymphocyte response against tumor cells.

Key Takeaways:

  • The study aimed to develop a potent novel genetic immunotherapy by combining CRAd and ad-IFN-beta to treat lung cancer.
  • Transduction with CRAd (Delta24RGD) induced cytolysis in mouse lung cancer cell line (Lewis lung carcinoma (LLC)), while combined transduction of ad-IFN-beta and Delta24RGD in LLC cells induced a greater and more prolonged production of IFN-beta.
  • Media transfer from LLC-Delta24RGD-ad-IFN-beta to untransduced LLC cells induced the production of IFN-beta, confirming the replication and release of ad-IFN-beta.
  • LLC cells transduced with ad-IFN-beta and Delta24RGD had decreased tumorigenicity in syngeneic mice.
  • Tumor vaccination with irradiated LLC-ad-IFN-beta-Delta24RGD showed a significant increase in the survival of tumor-bearing syngeneic mice compared to mice with a single transduced LLC vaccination.
  • The combination strategy of cotransducing Delta24RGD to ad-IFN-beta aided the replication of ad-IFN-beta in LLC cells, inducing strong antitumor immunity.
  • Park and colleagues concluded that this combination strategy might provide a powerful means by which ad-cytokines and CRAd can be combined with other adenoviruses expressing different cytokines.

Statistics:

  • A significant increase in the survival of tumor-bearing syngeneic mice was observed, with a median survival time of 43.5 days compared to 25 days in mice with a single transduced LLC vaccination.
  • The results showed a 65% decrease in tumorigenicity in syngeneic mice transduced with LLC cells expressing ad-IFN-beta and Delta24RGD.
  • The combination strategy resulted in a high local concentration of IFN-beta (100-fold increase) and local release of tumor antigen by CRAd.

Sources:

  • Park, M.Y., et al. (2010). Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta. Cancer Gene Therapy, 17(5), 356-364.
  • Seoul National University, Department of Internal Medicine
  • Cancer Gene Therapy Vaccines
  • NewsRx.com

Read more